BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 10021290)

  • 1. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study.
    Homesley HD; Bundy BN; Hurteau JA; Roth LM
    Gynecol Oncol; 1999 Feb; 72(2):131-7. PubMed ID: 10021290
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin.
    Gershenson DM; Morris M; Burke TW; Levenback C; Matthews CM; Wharton JT
    Obstet Gynecol; 1996 Apr; 87(4):527-31. PubMed ID: 8602303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary.
    Culine S; Kattan J; Lhomme C; Duvillard P; Michel G; Castaigne D; Leclere J; Pico J; Droz JP
    Gynecol Oncol; 1994 Jul; 54(1):47-53. PubMed ID: 7517380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized comparison of combination chemotherapy with etoposide, bleomycin, and either high-dose or standard-dose cisplatin in children and adolescents with high-risk malignant germ cell tumors: a pediatric intergroup study--Pediatric Oncology Group 9049 and Children's Cancer Group 8882.
    Cushing B; Giller R; Cullen JW; Marina NM; Lauer SJ; Olson TA; Rogers PC; Colombani P; Rescorla F; Billmire DF; Vinocur CD; Hawkins EP; Davis MM; Perlman EJ; London WB; Castleberry RP; ;
    J Clin Oncol; 2004 Jul; 22(13):2691-700. PubMed ID: 15226336
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy of advanced ovarian juvenile granulosa cell tumors.
    Schneider DT; Calaminus G; Wessalowski R; Pathmanathan R; Harms D; Göbel U
    Klin Padiatr; 2002; 214(4):173-8. PubMed ID: 12165898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor.
    Kang H; Kim TJ; Kim WY; Choi CH; Lee JW; Kim BG; Bae DS
    Gynecol Oncol; 2008 Oct; 111(1):106-10. PubMed ID: 18656249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic analysis of Japanese men with metastatic germ cell tumors showing favorable response to bleomycin, etoposide and cisplatin as first-line chemotherapy.
    Kumano M; Miyake H; Hara I; Muramaki M; Takenaka A; Fujisawa M
    Hinyokika Kiyo; 2007 Dec; 53(12):851-6. PubMed ID: 18203521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favorable outcome of ovarian germ cell malignancies treated with cisplatin or carboplatin-based chemotherapy: a Hellenic Cooperative Oncology Group study.
    Dimopoulos MA; Papadopoulou M; Andreopoulou E; Papadimitriou C; Pavlidis N; Aravantinos G; Aspropotamitis A; Anagnostopoulos A; Fountzilas G; Michalas S; Pectacides D
    Gynecol Oncol; 1998 Jul; 70(1):70-4. PubMed ID: 9698477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of children and adolescents with stage II testicular and stages I and II ovarian malignant germ cell tumors: A Pediatric Intergroup Study--Pediatric Oncology Group 9048 and Children's Cancer Group 8891.
    Rogers PC; Olson TA; Cullen JW; Billmire DF; Marina N; Rescorla F; Davis MM; London WB; Lauer SJ; Giller RH; Cushing B; ;
    J Clin Oncol; 2004 Sep; 22(17):3563-9. PubMed ID: 15337806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term results of first-line sequential high-dose etoposide, ifosfamide, and cisplatin chemotherapy plus autologous stem cell support for patients with advanced metastatic germ cell cancer: an extended phase I/II study of the German Testicular Cancer Study Group.
    Schmoll HJ; Kollmannsberger C; Metzner B; Hartmann JT; Schleucher N; Schöffski P; Schleicher J; Rick O; Beyer J; Hossfeld D; Kanz L; Berdel WE; Andreesen R; Bokemeyer C;
    J Clin Oncol; 2003 Nov; 21(22):4083-91. PubMed ID: 14568987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study.
    Dimopoulos MA; Papadimitriou C; Hamilos G; Efstathiou E; Vlahos G; Rodolakis A; Aravantinos G; Kalofonos H; Kouroussis C; Gika D; Skarlos D; Bamias A
    Gynecol Oncol; 2004 Dec; 95(3):695-700. PubMed ID: 15581984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of malignant ovarian germ cell tumor and sex cord tumors].
    Sugiyama T; Ohta S; Tomonari R; Kamura T
    Gan To Kagaku Ryoho; 2002 Aug; 29(8):1358-62. PubMed ID: 12214461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors.
    Pautier P; Gutierrez-Bonnaire M; Rey A; Sillet-Bach I; Chevreau C; Kerbrat P; Morice P; Duvillard P; Lhommé C
    Int J Gynecol Cancer; 2008; 18(3):446-52. PubMed ID: 18494093
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors and role of salvage surgery in chemorefractory ovarian germ cell malignancies: a study in Chinese patients.
    Li J; Yang W; Wu X
    Gynecol Oncol; 2007 Jun; 105(3):769-75. PubMed ID: 17459461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of metastatic stromal tumors of the ovary with cisplatin, doxorubicin, and cyclophosphamide.
    Gershenson DM; Copeland LJ; Kavanagh JJ; Stringer CA; Saul PB; Wharton JT
    Obstet Gynecol; 1987 Nov; 70(5):765-9. PubMed ID: 3658288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H; Rasmussen S; Simonsen E
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of early ovarian cancer: germ cell and sex cord-stromal tumors.
    Gershenson DM
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S62-72. PubMed ID: 7530680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.